Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38230
CAS Number:
106308-44-5
Rufinamida
Purity:
≥ 98 % (HPLC)
Synonym(s):
1-(2,6-Difluorobencil)-1 H -1,2,3-triazol-4-carboxamida
Documents
$18.53 /25 mg
Tamaño
Request Bulk Quote
Información del producto

Rufinamide is a triazole derivative known for its efficacy in treating epilepsy, particularly in patients with Lennox-Gastaut syndrome. This compound exhibits a unique mechanism of action, which involves the modulation of sodium channels, thereby stabilizing neuronal membranes and reducing seizure frequency. Its favorable pharmacokinetic profile allows for flexible dosing, making it a valuable option for both pediatric and adult patients.

In addition to its primary use in epilepsy management, Rufinamide shows promise in research settings, particularly in studies exploring its potential neuroprotective effects. Its ability to cross the blood-brain barrier enhances its relevance in neurological research, paving the way for further investigations into its applications in other seizure disorders and neurodegenerative diseases. With its established safety profile and growing body of research, Rufinamide stands out as a significant compound for both clinical and research applications in the field of neurology.

Número CAS
106308-44-5
Fórmula molecular
C10H8F2N4O
Peso molecular
238.2
Número MDL
MFCD00865314
Punto de fusión
239 - 243 °C
Información general
Número CAS
106308-44-5
Fórmula molecular
C10H8F2N4O
Peso molecular
238.2
Número MDL
MFCD00865314
Punto de fusión
239 - 243 °C
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Rufinamide is widely utilized in research focused on

  • Epilepsy Treatment: Primarily used as an anticonvulsant, it is effective in managing seizures associated with Lennox-Gastaut syndrome, providing relief for patients who do not respond to other medications.
  • Neuroscience Research: Researchers study its mechanisms to better understand seizure pathways and develop new treatments for various types of epilepsy, enhancing patient care and outcomes.
  • Drug Interaction Studies: Rufinamide serves as a model compound in pharmacokinetic studies to assess interactions with other antiepileptic drugs, helping to optimize combination therapies.
  • Clinical Trials: It is frequently included in clinical trials aimed at evaluating new therapeutic strategies for refractory epilepsy, contributing to advancements in treatment options.
  • Pharmaceutical Development: Its unique chemical structure allows for the exploration of novel formulations and delivery methods, potentially improving bioavailability and patient adherence.

Citas